Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.

View/ Open
Author
López-Beltrán, Antonio
Álvarez-Kindelan, J.
Luque, R.J.
Blanca, A.M.
Quintero, Ana
Montironi, Rodolfo
Cheng, Liang
González-Campora, R.
Requena-Tapia, M.J.
Publisher
WileyDate
2008Subject
Bladder cancerRecurrence
Urothelium
9q32–33
LOH
DBC1 locus
FGFR3
Cell cycle
METS:
Mostrar el registro METSPREMIS:
Mostrar el registro PREMISMetadata
Show full item recordAbstract
Tumour recurrence has a major impact on patients with non-invasive papillary urothelial
tumours of the bladder. To explore the role of DBC1 (deleted in bladder cancer 1 locus),
a candidate tumour suppressor gene located at 9q32–33, as prognostic marker we have
performed loss of heterozygosity (LOH) testing in 49 patients with primary papillary
urothelial tumours and associated normal urothelium. Data from the 38 tumours and
11 specimens of normal urothelium that were informative in the LOH study (D9S195
marker) showed that LOH in urothelium (45.4%) but not in non-invasive tumours (60.5%)
was associated with tumour recurrence (p = 0.026) but not to grade or progression. Also,
tumours whose normal urothelium had LOH were larger (p = 0.020) and showed cyclin
D1 over-expression (p = 0.032). Non-significant increased expression of p53, p21Waf1,
apoptotic index and tumour proliferation, and decreased expression of p27Kip1 or cyclin
D3 also characterized tumours whose normal urothelium had LOH. The expression of these
G1 –S modulators, apoptotic index and tumour proliferation was more heterogeneous in
papillary urothelial tumours, irrespective of having retained heterozygosity or LOH. Also,
Bax expression decreased in papillary urothelial tumours having LOH (p = 0.0473), but
Bcl-2 was unrelated to LOH status. In addition, FGFR3 protein expression decreased in
LOH tumours (p = 0.036) and in those having LOH in their normal urothelium (p = 0.022).
FGFR3 immunohistochemical expression was validated by western blot in selected cases. The
survival analysis selected LOH in normal urothelium as a marker of disease-free survival
(log-rank 5.32, p = 0.021), progression-free survival (log-rank 3.97, p = 0.046) and overall
survival (log-rank 4.26, p = 0.038); LOH in tumours was significant in progression-free
survival (log-rank 3.83, p = 0.042). It is concluded that LOH at the DBC1 locus in normal
urothelium seems to be relevant in the prognosis of non-invasive papillary tumours of the
bladder via selecting cases with increased proliferation, frequent alterations of the G1 –S
phase modulators, and decreased FGFR3 protein expression.
